undamentalytics Newsletter
Sign in

Irulya Therapeutics Inc. (IRLA) stock

Add to watchlist

Add holding +

NASDAQ: IRLA Nasdaq Biotechnology Next results ~November 12, 2026

Irulya Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds24 adding, 0 cuttingOf 3 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Irulya Therapeutics Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 16 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 357% and a beta of 1.9 against the S&P 500.
  • Heavily shorted. 15.3% of the shares available to trade are sold short (4.5 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$12.15 against an average estimate of -$12.39: beat by 1.9%
Share reaction
+5.3% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$1.20

Irulya Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week+6.9%
  • 1 month+14.9%
  • This year-95.0%
  • 1 year-89.8%
  • 5 years-99.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 14, 2026
Next results (est.)
November 16, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Leadership
  4. Leadership
  5. Leadership
  6. Leadership
  7. Announcement
  8. Results
  9. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Irulya Therapeutics Inc. valuation models and calculator

No model value for Irulya Therapeutics Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Irulya Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.82 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Irulya Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.20 (range −$1.40 to −$0.83) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.65 +99% — 0%
Next −$4.68 −28% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −31.1% on 90 days ago. In the last 30 days, 0 analysts raised Irulya Therapeutics Inc.'s forecast and 0 cut it.

Consensus EPS forecast Irulya Therapeutics Inc., last 90 days
−$30.00 −$20.00 −$10.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$5.30 Current fiscal year, 60 days ago: −$1.48 Current fiscal year, 30 days ago: −$3.65 Current fiscal year, 7 days ago: −$3.65 Current fiscal year, Now: −$3.65 −$3.65 Next fiscal year, 90 days ago: −$26.10 Next fiscal year, 60 days ago: −$5.76 Next fiscal year, 30 days ago: −$4.68 Next fiscal year, 7 days ago: −$4.68 Next fiscal year, Now: −$4.68 −$4.68

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$5.30−$26.10
60 days ago −$1.48−$5.76
30 days ago −$3.65−$4.68
7 days ago −$3.65−$4.68
Now −$3.65−$4.68

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$12.39 −$12.15 +1.9%
Mar 2026 −$52.00 $57.60 +210.8%
Dec 2025 −$45.00 −$152.00 −237.8%
Sept 2025 −$44.50 −$50.00 −12.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Oct 2026
Buy889%
Hold111%
Sell00%

Monthly trend

  1. Oct 20262619
  2. Sep 20261618
  3. Aug 2026527
  4. Jul 2026426

Counts of recommendations published by analysts covering Irulya Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.3%
of tradable shares
Days to cover
4.53
at average volume
Short interest, 1 month
+208%
to October 15, 2026
Held by institutions
12%
of shares
Held by insiders
0.3%
of shares
Employees
38
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IRLA−55%−95%+65%+78%+79%−95%
Industry peers (median)−35%−56%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IRLA58%8%42%50%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IRLA−91%−96%−52%−61%−58%−98%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 9, 2019: 100% from August 10, 2021 to March 20, 2026. Getting back needed a 150163% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$16.00 – $880.00
From 52-week high
−96.2%
vs 50-day average
+8.0%
vs 200-day average
−35.2%
Volatility (1 year)
357%
Beta vs S&P 500
1.86

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±15.6%
After a week
6 up, 6 down
typical move ±13.5%
After a month
4 up, 8 down
typical move ±29.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 +5.3% −0.7% +4.7% −11.0%
February 12, 2026 −67.2% −1.5% −75.4% −83.0%
November 12, 2025 −6.1% −1.6% +7.8% +135.8%
August 11, 2025 +10.9% +0.9% +1.2% −2.4%
May 13, 2025 −18.3% +0.8% −1.0% +16.5%
March 24, 2025 −0.7% +2.0% −3.6% −23.2%
November 13, 2024 +13.1% −0.6% +9.5% +20.8%
August 13, 2024 −20.3% +2.0% −11.6% +6.5%
July 24, 2023 −25.9% +0.7% −24.1% −21.5%
January 30, 2023 −9.3% +0.2% −4.6% −11.9%
August 1, 2022 −2.1% −1.0% +13.3% −8.2%
May 12, 2022 +7.6% +2.3% +5.1% −13.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$4.7M
Institutions reporting
24
Positions opened / closed
24 / 0

Top buyers and sellers, Q2 2026: 24 institutions bought and 0 sold ; the biggest buyer was Ikarian Capital, LLC (+72K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Ikarian Capital, LLC $1.3M 72K 27.7% —
Millennium Management LLC $1.3M 71K 27.1% —
Squadron Capital Management LLC $734,421 40K 15.5% —
Shay Capital LLC $329,272 17K 6.9% —
Boothbay Fund Management, LLC $253,041 14K 5.3% —
Jane Street Group, LLC $229,958 13K 4.8% —
Vanguard Capital Management LLC $219,080 12K 4.6% —
Cormorant Asset Management, LP $100,009 5K 2.1% —
UBS Group AG $86,039 5K 1.8% —
Morgan Stanley $74,288 4K 1.6% —
Vanguard Fiduciary Trust Co $65,739 4K 1.4% —
Blackrock, Inc. $30,959 2K 0.7% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Irulya Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $173,500 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $173,500 net selling
Insider Date Trade Shares Price Value
Benatti Luca Director December 26, 2025 Sell 50,000 $3.47 $173,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 16, 2026 estimated from the company's past filing pattern, not announced

  • August 14, 2026
  • February 12, 2026
  • November 12, 2025
  • August 11, 2025
  • May 13, 2025
  • March 24, 2025

Recent SEC filings

Data status

When each part of this page on Irulya Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Irulya Therapeutics Inc. in brief

What does Irulya Therapeutics Inc. do?
Irulya Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Irulya Therapeutics Inc.'s stock ticker?
Irulya Therapeutics Inc. trades under the ticker IRLA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Irulya Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Ikarian Capital, LLC, Millennium Management LLC and Squadron Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Irulya Therapeutics Inc. stock?
Over the last 12 months, Irulya Therapeutics Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Irulya Therapeutics Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Irulya Therapeutics Inc. announces its own schedule.